Alzheimer's research & therapy · 2018
Human fibroblast and stem cell resource from the Dominantly Inherited Alzheimer Network.
СтатьяПоддержка NIH: внешняя программаПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Karch Celeste M, Hernández Damián, Wang Jen-Chyong, Marsh Jacob, Hewitt Alex W, Hsu Simon, Norton Joanne, Levitch Denise, Donahue Tamara, Sigurdson Wendy, Ghetti Bernardino, Farlow Martin, Chhatwal Jasmeer, Berman Sarah, Cruchaga Carlos, Morris John C, Bateman Randall J, Dominantly Inherited Alzheimer Network (DIAN), Pébay Alice, Goate Alison M
Аннотация
BACKGROUND: Mutations in amyloid precursor protein (APP), presenilin 1 (PSEN1) and presenilin 2 (PSEN2) cause autosomal dominant forms of Alzheimer disease (ADAD). More than 280 pathogenic mutations have been reported in APP, PSEN1, and PSEN2. However, understanding of the basic biological mechanisms that drive the disease are limited. The Dominantly Inherited Alzheimer Network (DIAN) is an international observational study of APP, PSEN1, and PSEN2 mutation carriers with the goal of determining the sequence of changes in presymptomatic mutation carriers who are destined to develop Alzheimer disease.
RESULTS: We generated a library of 98 dermal fibroblast lines from 42 ADAD families enrolled in DIAN. We have reprogrammed a subset of the DIAN fibroblast lines into patient-specific induced pluripotent stem cell (iPSC) lines. These cells were thoroughly characterized for pluripotency markers.
CONCLUSIONS: This library represents a comprehensive resource that can be used for disease modeling and the development of novel therapeutics.
RESULTS: We generated a library of 98 dermal fibroblast lines from 42 ADAD families enrolled in DIAN. We have reprogrammed a subset of the DIAN fibroblast lines into patient-specific induced pluripotent stem cell (iPSC) lines. These cells were thoroughly characterized for pluripotency markers.
CONCLUSIONS: This library represents a comprehensive resource that can be used for disease modeling and the development of novel therapeutics.